Evidence map›Paper›PMID 34545312›Full record

ArticleCase reports in gastrointestinal medicine2021

A Unique Case of Mantle Cell Lymphoma Masquerading as a Cecal Mass.

Sarahi Herrera-Gonzalez, Dema Shamoon, Tingliang Shen, Simon Badin, Yatinder Bains

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in gastrointestinal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarahi Herrera-GonzalezDepartment of Internal Medicine, Jersey City Medical Center, 355 Grand St, Jersey City, NJ 07002, USA.ORCID https://orcid.org/0000-0002-7761-1788
Dema ShamoonDepartment of Gastroenterology, St Michael's Medical Center, 111 Central Ave, Newark, NJ 07102, USA.ORCID https://orcid.org/0000-0003-2032-7695
Tingliang ShenDepartment of Pathology, Jersey City Medical Center, 355 Grand St, Jersey City, NJ 07002, USA.ORCID https://orcid.org/0000-0002-0878-4175
Simon BadinDepartment of Oncology, Jersey City Medical Center, 355 Grand St, Jersey City, NJ 07002, USA.ORCID https://orcid.org/0000-0001-5606-8053
Yatinder BainsDepartment of Gastroenterology, St Michael's Medical Center, 111 Central Ave, Newark, NJ 07102, USA.ORCID https://orcid.org/0000-0002-6331-1194
Jersey City Medical Center · USSaint Michael's Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL), a type of B-cell non-Hodgkin's lymphoma, is a rare and aggressive disease with a poor prognosis due to its advanced presentation at diagnosis. It is characterized by a translocation in the Bcl-1 gene, which results in overexpression of cyclin D1. MCL is frequently seen in the form of multiple lymphomatous polyposis (MLP) in which innumerable polyps are observed in the gastrointestinal (GI) tract. In rare instances, MCL presents a single mass. The most common presentation involves male patients in their sixties, with generalized lymphadenopathy, extranodal involvement, and B symptoms (night sweats, fever, and weight loss). Endoscopic findings of MLP include cerebroid folding of the gastric mucosa and innumerable polyps extending from the duodenum to the large intestine and are reported in approximately 9% of all GI lymphomas. Less commonly, only 2-4% of GI malignancies present as a primary GI MCL as a single mass, usually in the stomach and ileocecal region in the intestine. Radiologic findings include lymphadenopathy, splenomegaly, multiple polyposis, or wall thickening with ulceration or mass formation. In most instances, advanced disease is found at diagnosis, for which 5-year survival ranges only from 26 to 46%, even when appropriate treatment is initiated. High mitotic rate, or Ki-67 index, is of prognostic value and is associated with poor prognosis. Treatment involves conventional chemo-immunotherapy consisting of R CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or RB (rituximab and bendamustine), with the latter being better tolerated and associated with longer progression-free survival. Surgical resection is usually limited to patients in which complications are seen such as bleeding, perforation, or bowel obstruction. We present a unique case of a 70-year-old male with nonbilious, nonbloody emesis, and symptomatic anemia who was found to have a cecal mass consistent with MCL.

Identifiers

PMID34545312
PMCPMC8449714
OpenAlexW3199243553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.